Loading stock research
Loading stock research…
No token price observed
Observation time unavailableUnavailable
Buy from your own wallet on Solana mainnet. You review and sign every transaction.
Checking whether mainnet purchases are available…
You sign in your own wallet. Ovelo never holds your keys or funds.
Daily closes of BMY, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
What you would hold, where it trades and where these numbers come from.
Observation time unavailableUnavailable
The company behind BMY.
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $48.20B |
| Revenue (annual) | 31 Dec 2024 | $48.30B |
| Revenue (annual) | 31 Dec 2023 | $45.01B |
| Revenue (annual) | 31 Dec 2022 | $46.16B |
| Net income (annual) | 31 Dec 2025 | $7.05B |
| Net income (annual) | 31 Dec 2024 | −$8.95B |
| Net income (annual) | 31 Dec 2023 | $8.03B |
| Net income (annual) | 31 Dec 2022 | $6.33B |
| Diluted EPS (annual) | 31 Dec 2025 | 3.46 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | −4.41 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | 3.86 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | 2.95 USD/share |
| Total assets (annual) | 31 Dec 2025 | $90.04B |
| Total assets (annual) | 31 Dec 2024 | $92.60B |
| Total assets (annual) | 31 Dec 2023 | $95.16B |
| Total assets (annual) | 31 Dec 2022 | $96.82B |
| Total debt (annual) | 31 Dec 2025 | $47.14B |
| Total debt (annual) | 31 Dec 2024 | $51.20B |
| Total debt (annual) | 31 Dec 2023 | $41.46B |
| Total debt (annual) | 31 Dec 2022 | $40.72B |
| Operating cash flow (annual) | 31 Dec 2025 | $14.16B |
| Operating cash flow (annual) | 31 Dec 2024 | $15.19B |
| Operating cash flow (annual) | 31 Dec 2023 | $13.86B |
| Operating cash flow (annual) | 31 Dec 2022 | $13.07B |
| Free cash flow (annual) | 31 Dec 2025 | $12.85B |
| Free cash flow (annual) | 31 Dec 2024 | $13.94B |
| Free cash flow (annual) | 31 Dec 2023 | $12.65B |
| Free cash flow (annual) | 31 Dec 2022 | $11.95B |
| Revenue (quarterly) | 30 Sept 2026 | $13.07B |
| Revenue (quarterly) | 30 Jun 2026 | $12.97B |
| Revenue (quarterly) | 31 Mar 2026 | $11.49B |
| Revenue (quarterly) | 31 Dec 2025 | $12.50B |
| Revenue (quarterly) | 30 Sept 2025 | $12.22B |
| Net income (quarterly) | 30 Sept 2026 | $2.16B |
| Net income (quarterly) | 30 Jun 2026 | $3.32B |
| Net income (quarterly) | 31 Mar 2026 | $2.68B |
| Net income (quarterly) | 31 Dec 2025 | $1.09B |
| Net income (quarterly) | 30 Sept 2025 | $2.20B |
| Diluted EPS (quarterly) | 30 Sept 2026 | 1.05 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | 1.62 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | 1.31 USD/share |
| Diluted EPS (quarterly) | 31 Dec 2025 | 0.53 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | 1.08 USD/share |
Reported dividends, splits and filings, each linked to its source.
Recent headlines about the company.